Lupus & antiphospholipid syndrome
Development and validation of a EULAR disease activity score in antiphospholipid syndrome
Authors' conclusion
Using data-driven and consensus methodology, EAPSDAS was developed and initial validation was performed.
Study context
- Population
- Task Force members, international antiphospholipid syndrome (APS) experts/collaborators, patients with primary APS and healthcare professionals24 Task Force members · 53 APS experts · 65 patients · 21 HCPs
- Outcome
- EAPSDAS development
Methodological detailssystematic literature review, surveys, Delphi methodology, real-world clinical vignettes
- Systematic literature review
- Surveys
- Delphi methodology
- Real-world clinical vignettes
Performance
As reported in the abstract
- Items representing APS activity generated
- 170
- Deduplicated candidate items rated
- 140
- Items in thrombotic/microvascular/nonthrombotic (TMN) scale (≥75% vote threshold and Delphi consensus)
- 24
- Items in obstetric scale
- 6
- Vignettes rated (3 versions each) for item scoring
- 60
Original publication
Development and validation of a EULAR disease activity score in antiphospholipid syndrome. Ann Rheum Dis. Published 19 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →